Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M0003
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Administration
- Oral
01
Overview
M0003 is an investigational oral prokinetic small-molecule drug being studied in combination with stable proton pump inhibitor (PPI) therapy to improve upper gastrointestinal motility and related symptoms in patients with acid-related disorders. In a randomized trial design, patients on a stable PPI dose receive M0003 tablets or placebo three times daily, suggesting that the agent is intended to enhance gastric emptying or esophageal/gastric motility rather than acid suppression itself. The precise molecular target, pharmacology, and sponsoring company have not been publicly disclosed, and no approved medical use has been reported.
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on M0003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M0003.